Brief: Sinomab Bioscience Says Investigational New Drug Application Approval For IBD Of SM17 By NMPA
24/02/2026 15:17
Feb 24 (Reuters) - SinoMab BioScience Ltd 3681.HK: INVESTIGATIONAL NEW DRUG APPLICATION APPROVAL FOR IBD OF SM17 BY NMPA Further company coverage: 3681.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sinomab Bioscience
See all newsBrief: Sinomab Bioscience Posts HY Loss Of RMB127.4 Million
Brief: Sinomab Bioscience Says Fang Liang Resigns As Executive Director
Brief: Sinomab Bioscience Announces Major Deal For Disposal Of Suzhou Property And Facility For RMB280 MLN
Brief: SinoMab Bioscience Appoints Fang Liang As Executive Director
Brief: Hainan Haiyao Plans To Unload Stake In Sinomab Bioscience